Zeaxanthin in metastatic cancer, alone or with pembrolizumab
Part of Cancer clinical trials.
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have stage 3 that cannot be removed or stage 4 cancer that has been confirmed by pathology
- Your cancer has gotten worse despite standard treatments that are known to help (or those treatments aren’t tolerated for your cancer type)
- You can do daily activities fairly well (ECOG performance status 0, 1, or 2)
- Your blood counts and organ tests are within required ranges (for example, neutrophils and platelets must meet minimums; liver and kidney numbers must be below set limits)
- You are able and willing to sign informed consent and are expected to live at least 3 months
- You can swallow pills and you are not pregnant or breastfeeding; you must use effective birth control during the study and for 90 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.